双位EZH2抑制剂:药物化学的最新进展
1State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology Department of Orthodontics, Sichuan University, Chengdu, 610041, Sichuan, China.
结合Enhancer of zeste homolog 2 (EZH2) 抑制与其他点的双抑制剂,有望改善癌症治疗. 与单一向药物相比,这些新药具有更高的疗效和更少的副作用.
科学领域:
- 表观遗传学和癌症治疗方法
- 药理学和药物设计
背景情况:
- 增强质同源2 (EZH2) 是一个关键的表观遗传调节器,与瘤进展有关.
- EZH2抑制剂被研究为抗癌药物,但单一向方法面临诸如耐药性等挑战.
- 双目标抑制策略为改善治疗结果提供了潜力.
研究的目的:
- 审查针对EZH2和其他蛋白质的双重抑制剂的最新进展.
- 强调这些双重抑制剂的合理设计,结构-活性关系和安全概况.
- 评估双 EZH2 向剂的临床潜力.
主要方法:
- 关于双 EZH2 抑制剂的最近研究的文献综述.
- 对双重向药物的合理药物设计原则的分析.
- 评估结构-活动关系 (SAR) 和安全数据.
主要成果:
- 针对EZH2的双重抑制剂与BRD4,PARP1或EHMT2结合,显示出增强的抗瘤疗效.
- 具体的例子,如EZH1/2抑制剂HH-2853,显示了改善的治疗特征.
- 这些双重目标策略在克服阻力和减少副作用方面表现有前途.
结论:
- 针对EZH2的双抑制剂代表了有希望的下一代癌症治疗药物.
- 对合理设计和临床评估进行进一步的研究是有必要的.
- 这些药物具有在瘤学中临床应用的巨大潜力.
更多相关视频
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
10:26Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
Published on: January 16, 2015
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
E2 Reaction: Stereochemistry and Regiochemistry
When a substrate with two different β hydrogens undergoes an E2 elimination, the presence of a strong base can yield two regioisomeric alkenes. The more-substituted alkene is the major...
Drug Discovery: Overview
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
